Spyre Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio874.9111.8812.50
P/B Ratio2.644.210.552.792.70
Price/Tangible Book3.780.552.792.70
Enterprise Value Ratios
EV/Revenue1082.036.78
Profitability & Returns
Return on Equity (ROE)-0.59%-2.89%-1.25%-0.59%-0.81%
Return on Assets (ROA)-0.27%-0.36%-0.59%-0.30%-0.42%
Return on Capital Employed (ROCE)-0.38%-0.38%-1.50%-0.73%-0.56%
Leverage & Solvency Ratios
Debt/Equity0.090.070.04
Liquidity Ratios
Current Ratio11.2610.684.254.919.11
Quick Ratio11.1610.613.834.668.90
Efficiency Ratios
Asset Turnover0.000.030.14
Yield & Distribution Ratios
Earnings Yield-0.15%-0.44%-3.03%-0.28%-0.21%
FCF Yield-0.12%-0.13%-2.90%-0.23%-0.21%
Buyback Yield-5.82%-1.05%-0.28%-0.23%-0.67%